RE:RE:RE:RE:Is this the year?I'm having trouble reconciling Shawn's wording in the NR with the longer timing you're suggesting Eogan. His words could easily be interpreted to mean that they will submit data on the first 25 to the FDA shortly after treating twenty five patients, maybe at 90 days post treatment.
“It is exciting to see Theralase® clear another hurdle by treating the first patient in the US and move one step closer to achieving its next milestone of enrolling and treating twenty-five patients in early 2021. Once completed, Theralase® plans to submit the clinical assessment data on the first twenty-five patients treated in Study II to the FDA for consideration of Break Through Designation (“BTD”) status.” Eoganacht wrote: An FDA standard review takes 10 months but Theralase has FTD which makes it eligible for priority review, the goal of which is for the FDA to take action on an application within 6 months.
chry200030 wrote:
FDA response takes 6 months? Meanwhile patients are dying !!!! Doesn't make sense...!!!